Geoffrey Liu, MSc, MD, is a senior scientist at Princess Margaret Cancer Centre and a professor in the Epidemiology Division at Dalla Lana School of Public Health of the University of Toronto in Canada.

Charu Aggarwal, MD, MPH, is a physician leader in Airways Malignancies Research, director of Precision Oncology Innovation at Penn Center for Cancer Care Innovation, section chief of Head & Neck and Thoracic Cancers, Hematology-Oncology, and the Leslye M. Heisler Professor for Lung Cancer Excellence at Penn Medicine in Philadelphia, Pennsylvania.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

Videos

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Pooled Data for Taletrectinib in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Addressing CNS Involvement in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Selecting a TKI in ROS1+ NSCLC Management

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

Treatment Sequencing Decisions in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Geoffrey Liu, MSc, MD

Articles